Inebilizumab-cdonAmerican Society of Health-System PharmacistsAmerican Society of Health-System Pharmacists2020DOI 10.1093/ajhp/zxaa277
Inebilizumab: First ApprovalJames E. FramptonSpringer International Publishing AG2020DOI 10.1007/s40265-020-01370-4
Inebilizumab for Treatment of IgG4-Related DiseaseStone, John H.Massachusetts Medical Society2024DOI 10.1056/nejmoa2409712
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trialRensel, MarySAGE Publications2022DOI 10.1177/13524585211047223
Sensitivity Analysis of the Primary Endpoint from the N-MOmentum Study of Inebilizumab in NMOSDBruce AC CreeSAGE Publications2021DOI 10.1177/1352458521988926
Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled TrialCory PeruginoSpringer Science and Business Media LLC2023DOI 10.1007/s40744-023-00593-7
Pharmacodynamic Modelling and Exposure–response Assessment of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum DisordersYan, LiWiley2022DOI 10.1111/bcp.15332
A Novel Class of Bis- and Tris-Chelate Diam(m)inebis(dicarboxylato)platinum(IV) Complexes as Potential Anticancer ProdrugsVarbanov, Hristo P.Journal of Medicinal Chemistry2014DOI 10.1021/jm500791c
Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical StudiesChen, DingMultidisciplinary Digital Publishing Institute (MDPI)2016DOI 10.3390/jcm5120107
Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): a Double-blind, Randomised Placebo-controlled Phase 2/3 TrialCree, Bruce A CThe Lancet2019DOI 10.1016/s0140-6736(19)31817-3
A Multicenter Phase I Study of Inebilizumab, a Humanized anti-CD19 Monoclonal Antibody, in Japanese Patients with Relapsed or Refractory B-cell Lymphoma and Multiple MyelomaOhmachi, KenCarden Jennings Publishing2019DOI 10.1007/s12185-019-02635-9